Arabic Arabic English English French French German German
dark

Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease

Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease, announced top-line interim results from a global clinical validation study of its AlzoSure® Predict prognostic biomarker test, which can accurately predict progression to Alzheimer’s disease years before symptoms appear. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

Next Post

InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China

Related Posts
Total
0
Share